Journal article · 2025 · Open access

Cancer risk of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs among older Americans with rheumatoid arthritis

Shyfuddin Ahmed, Ruth M. Pfeiffer, Sarah S. Jackson, Minkyo Song, Xavier Mariette, Raphaèle Séror, Eric A. Engels

Rheumatology, 64(7), 4172–4180 · Published 10 February 2025 · DOI 10.1093/rheumatology/keaf092

Open PDFView at the publisherCite this paper

In brief

“Cancer risk of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs among older Americans with rheumatoid arthritis” is a 2025 journal article by Shyfuddin Ahmed and 6 co-authors, published in Rheumatology. OpenAlex counts 12 citations as of 19 November 2026, which puts it in the top 7% of works published in 2025 by citations. It is open access under a public domain licence: the full text is free to read at PubMed Central.

Citations
12
Most cited in
2026 (10)
Field-weighted impact
6.28
References
36
Authors
7

Abstract

OBJECTIVE: To examine cancer risk associated with Janus kinase inhibitors (JAKis) and biological DMARDs (bDMARDs) in patients with RA. METHODS: Case-control study of patients with RA age 65 years or older in the US Surveillance, Epidemiology, and End Results (SEER)-Medicare database during 2014-2019. Cases were individuals with a first cancer diagnosed in SEER registries (N = 12 463). Cancer-free controls (N = 38 345) were Medicare beneficiaries residing in SEER areas. Exposure to JAKis, tumour necrosis factor inhibitors (TNFis) and other bDMARDs was ascertained using prescription claims. Logistic regression was used to estimate adjusted odds ratios (ORs). RESULTS: 1.9% of cases and 2.0% of controls were prescribed a JAKi. Among patients prescribed a JAKi, the median duration of documented exposure was 1.8 years. Overall cancer risk was not associated with exposure to JAKis (adjusted OR 1.04, 95% CI 0.87-1.26), TNFis (0.98, 0.92-1.05) or other bDMARDs (0.98, 0.90-1.07). However, JAKi exposure was associated with significantly increased risk of lung cancer (OR 1.40, 95% CI 1.06-1.87), especially in males (2.12, 1.14-3.94) and with >2 years of JAKi exposure (1.52, 1.01-2.28). Among females, JAKi exposure was associated with lower risk of breast cancer (OR 0.62, 95% CI 0.39-0.97). CONCLUSIONS: Among older adults with RA, JAKi exposure over a median of 1.8 years was not associated with an overall increase in cancer risk. However, lung cancer risk was elevated, supporting clinical caution in prescribing this medication class to smokers. Further research is needed to understand the role of the JAK/STAT pathway in cancer.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Ahmed, S., Pfeiffer, R. M., Jackson, S. S., Song, M., Mariette, X., Séror, R., & Engels, E. A. (2025). Cancer risk of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs among older Americans with rheumatoid arthritis. Rheumatology, 64(7), 4172–4180. https://doi.org/10.1093/rheumatology/keaf092

MLA 9

Ahmed, Shyfuddin, et al. “Cancer risk of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs among older Americans with rheumatoid arthritis.” Rheumatology, vol. 64, no. 7, 2025, pp. 4172–4180. https://doi.org/10.1093/rheumatology/keaf092.

Chicago

Ahmed, Shyfuddin, Ruth M. Pfeiffer, Sarah S. Jackson, Minkyo Song, Xavier Mariette, Raphaèle Séror, and Eric A. Engels. 2025. “Cancer risk of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs among older Americans with rheumatoid arthritis.” Rheumatology 64 (7): 4172–4180. https://doi.org/10.1093/rheumatology/keaf092.

Harvard

Ahmed, S. et al. (2025) ‘Cancer risk of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs among older Americans with rheumatoid arthritis’, Rheumatology, 64(7), pp. 4172–4180. doi:10.1093/rheumatology/keaf092.

IEEE

S. Ahmed et al., “Cancer risk of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs among older Americans with rheumatoid arthritis,” Rheumatology, vol. 64, no. 7, pp. 4172–4180, 2025, doi: 10.1093/rheumatology/keaf092.

BibTeX

@article{ahmed2025cancer,
  title     = {{Cancer risk of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs among older Americans with rheumatoid arthritis}},
  author    = {Ahmed, Shyfuddin and Pfeiffer, Ruth M. and Jackson, Sarah S. and Song, Minkyo and Mariette, Xavier and Séror, Raphaèle and Engels, Eric A.},
  journal   = {Rheumatology},
  year      = {2025},
  volume    = {64},
  number    = {7},
  pages     = {4172--4180},
  doi       = {10.1093/rheumatology/keaf092},
  url       = {https://doi.org/10.1093/rheumatology/keaf092}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • JAK inhibitors
  • biologic DMARDs
  • rheumatoid arthritis
  • cancer risk
  • lung cancer
  • breast cancer
  • tumor necrosis factor inhibitors
  • older adults

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Ahmed, S., Pfeiffer, R. M., Jackson, S. S., Song, M., Mariette, X., Séror, R., & Engels, E. A. (2025). Cancer risk of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs among older Americans with rheumatoid arthritis. Rheumatology, 64(7), 4172–4180. https://doi.org/10.1093/rheumatology/keaf092

How many times has this paper been cited?

12 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at PubMed Central: sign in and open the PDF from this page.

Who wrote this paper?

Shyfuddin Ahmed, Ruth M. Pfeiffer, Sarah S. Jackson, Minkyo Song, Xavier Mariette, Raphaèle Séror, Eric A. Engels.

What is the DOI of this paper?

10.1093/rheumatology/keaf092, permanently at https://doi.org/10.1093/rheumatology/keaf092. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.